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Abstract
Background: Video-assisted thoracoscopic (VATS) surgery contributes to
improved survival, adjuvant chemotherapy delivery and less postoperative com-
plications. Nonintubated thoracic surgery (NITS) VATS procedures improves
immunological responses in lung cancer patients; however, there is no data
regarding adjuvant chemotherapy delivery effectiveness following NITS lobecto-
mies. In this study, we aimed to compare protocol compliance and toxic compli-
cations during adjuvant chemotherapy after intubated and nonintubated VATS
lobectomies in non-small cell lung cancer (NSCLC).
Methods: We retrospectively reviewed the medical records of 66, stage IB–IIIB
NSCLC patients who underwent intubated or nonintubated VATS lobectomy
and received adjuvant chemotherapy.
Results: A total of 38 patients (17 males, mean age 64 years) underwent conven-
tional VATS and 28 (7 males; mean age 63 years) uniportal VATS NITS. Both
groups had comparable demographic data, preoperative pulmonary function, and
Eastern Cooperative Oncology Group (ECOG) status. Among the intubated and
nonintubated patients, 82% and 75% were diagnosed with adenocarcinoma, respec-
tively. The incidence of adenocarcinoma and squamous cell carcinoma cases were
similar in both groups; however, the pathological staging showed significant differ-
ences, as 5 (18%) nonintubated patients had stage IB lung cancer, compared with
the intubated group (P = 0.01). Further distribution of stages was similar between
the groups. We observed significant differences in chest tube duration and opera-
tion time in the nonintubated group (P < 0.01). Among nonintubated patients,
92% completed the planned chemotherapy protocol, compared to 71% of the
intubated group (P = 0.035). Grade 1/2 toxicity occurred significantly more often
in the intubated group (16% vs. 0%, P = 0.03) and there was a lower incidence of
grade 4 neutropenia in the nonintubated group (0% vs. 16%, P = 0.03).
Conclusions: Our results showed that the nonintubated procedure resulted in
improved adjuvant chemotherapy compliance and lower toxicity rates after lobectomy.
Key points
Significant findings of the study
• Oncological advantage of the non-intubated thoracic surgery: better compli-
ance with therapy protocol.
What this study adds
• NITS lobectomies contribute to better administration of adjuvant chemother-
apy with the planned cycle number and dosage.
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Introduction
Excessive surgical procedures can cause an altered,
uncompensated proinflammatory response to surgical
trauma and ventilation; therefore, video-assisted
thoracoscopic surgery (VATS) is regarded as more reliable
with a lower number of postoperative complications and
morbidity.1, 2 Unlike thoracotomy, performing VATS can
infer several immunological benefits associated with a
favorable immune response to surgery. Thoracotomy can
result in increased secretion of interleukins and decreased
cellular functions that influence postoperative complica-
tions, antitumor immunity and infections, similar to other
surgical procedures.3 Patients undergoing thoracotomy
have been reported to show a profound interleukin (IL)-6,
IL-8, IL-10 and tumor necrosis factor (TNF)-α production
in serum compared to that in patients undergoing VATS
lung resection, which has been shown to affect further
proinflammatory properties and host defense against infec-
tions.4, 5 In addition, IL-6 and IL-10 plasma concentrations
have been shown to be elevated at the time of wound clo-
sure and on the first postoperative day, predicting a signifi-
cant probability of postoperative complications and
emerging as a risk factor in these patients.6 Furthermore,
there are emerging evidences to suggest that there is a rela-
tionship between lymphocyte, natural killer (NK) cell
count, function, signaling and surgical approach. Thoracot-
omy has previously been reported to cause a significant
reduction in CD4+ T cell count and a prolonged NK cell
suppression when compared with VATS resection.7
Applying a VATS approach seems to be superior to tho-
racotomy in treating immunocompromised lung cancer
patients in order to minimize the risk of postoperative
mortality, complications and support the efficacy of adju-
vant chemotherapy.8 There is increasing evidence that
VATS lung resection contributes to better adjuvant chemo-
therapy compliance, improved tolerance and mitigation of
hematological toxicity compared to open thoracic surgery.9
Of note, thoracoscopic procedures have also been reported
to facilitate the delivery of adjuvant chemotherapy and sig-
nificant differences in patients have been observed who
have received reduced chemotherapy doses or an incom-
plete protocol compared to thoracotomy.10
All these results indicate that there is a demand to
develop a less invasive version of VATS surgery to achieve
even better surgical outcomes in lung cancer patients: the
innovation of uniportal, especially nonintubated VATS
surgery, has already been confirmed as being advantageous
in early and advanced cases of non-small cell lung cancer
(NSCLC).11 Nonintubated uniportal operations have been
reported to cause a significantly lower negative impact on
NK cells and lymphocytes, resulting in shortened hospital
stay and lower morbidity rates.12
However, no data is available on whether nonintubated
VATS lobectomies are able to achieve better oncological
outcomes in adjuvant chemotherapy doses, completed
cycles or hematological toxicity. Based on the immuno-
logical benefits, in this retrospective study we hypothe-
sized that patients who underwent nonintubated
thoracoscopic surgery (NITS) present better protocol
compliance to adjuvant chemotherapy in terms of admin-
istered dosage and cycle completion. Our aim was to
analyze the differences in chemotherapy features, hemato-
logical toxicities and postoperative complications between
intubated and nonintubated patients after VATS
lobectomy.
Methods
Study design and patient selection
A retrospective analysis was conducted of 66 IB–IIIB
NSCLC patients who received adjuvant chemotherapy
(with or without radiotherapy) after undergoing either
intubated and nonintubated VATS procedures between
January 2014 and December 2019 at the Department of
Surgery, University of Szeged. Due to the adjuvant chemo-
therapy protocols used, patients were treated at the Depart-
ment of Pulmonology, University of Szeged, Hospital of
Chest Diseases, Deszk. Between January 2014 and
December 2016, 38 patients underwent standard multi-
portal VATS lobectomies with general anesthesia under
one-lung mechanical ventilation as previously described.13
Between January 2017 and December 2019, nonintubated
uniportal VATS lobectomy was performed in 28 patients,
as suggested in previous studies.14, 15 All patients were
staged according to the International Association for the
Study of Lung Cancer (IASLC) eighth TNM staging guide-
line for lung cancer16 and underwent preoperative chest
computed tomography (CT), brain CT/magnetic resonance
imaging (MRI), bone scan, abdominal ultrasound/CT,
bronchoscopy, pulmonary function testing and laboratory
examinations. Positron emission tomography (PET) was
not available for all patients. Patients provided a written
informed consent to surgery and chemotherapy and the
research was approved by the ethics committee of the
Hungarian Medical Research Council.
Data were collected from institutional databases and
included demographic features, body mass index (BMI),
Eastern Cooperative Oncology Group (ECOG) status,
smoking habits, pulmonary function testing, histological
type, pathological grade, operative time, chest tube dura-
tion, postoperative complications and adjuvant chemother-
apy characteristics.
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Surgery
Patient selection
Oncologically the patient selection was similar in both
groups. According to a consensus meeting recommenda-
tions for VATS lobectomy, patients with early stage lung
cancer (<7 cm, N0, and N1 patients) were scheduled.17 The
surgical procedure of VATS lobectomy in the intubated and
in the nonintubated groups were the same, but for the non-
intubated method there were some exclusion criteria because
of patient safety: suspicion of difficult intubation, full anti-
coagulation, reflux disease, cardiac instability or mental
problem.18 In our current practice, patients with body mass
index (BMI) of <30 were indicated for NITS.
Surgical procedure
We performed multiportal and uniportal VATS methods
for intubated and NITS procedures as previously men-
tioned in the literature.19–21 The multiportal procedure was
used until June 2015.
For NITS, at the incision site in the fifth intercostal
space in the mid-axillary line, 2% lidocaine (5 mg/kg) was
injected subcutaneously, and an incision made. After enter-
ing the chest cavity, the lung gradually became atelectatic.
An intercostal nerve blockade was performed using 0.5%
bupivacaine between the second and fifth intercostal nerves
and bupivacaine was also used for the vagus nerve block-
ade (right side in the upper mediastinum; left side in the
aortopulmonary window). After this point, endoscopic
instrument manipulation was the same in both groups, but
in the nonintubated group the patients were able to
breathe spontaneously without mechanical ventilation.
Anesthesiology
With regard to the NITS surgery, the exclusion criteria are
detailed above. In addition to standard monitoring (ECG, O2
saturation, noninvasive blood pressure), depth of anesthesia
monitoring using the Bispectral Index (BIS; Medtronic Vista)
and invasive blood pressure (IBP) measurements were per-
formed. Midazolam and fentanyl were administered prior to
surgery. Anesthesia was induced and maintained with closed-
loop titration of propofol administered via target control infu-
sion to maintain the BIS at 40–60 according to the published
recommendations.22 After an adequate depth of anesthesia
was achieved, a laryngeal mask was inserted for airway main-
tenance. Spontaneous breathing was also maintained
throughout and ventilation was monitored using cap-
nography. Oxygen and air mixture were supplemented via a
T-piece and FiO2 was titrated to keep the SpO2 above 92%.
For intubated cases we performed the gold standard
technique, with relaxation and intubation, and one lung
ventilation.
Adjuvant chemotherapy
Postoperatively, a multidisciplinary team including a
pathologist, respiratory physicians, oncologists and thoracic
surgeons discussed every histopathology result and decided
on the necessity of adjuvant chemotherapy based on for-
mer recommendations.23–25 Patients were staged using the
eighth edition TNM staging system and those with ECOG
0 or 1 were discussed and chemotherapy regimens were
determined based on the physician’s preference. All
patients were scheduled to receive four-cycle platinum-
based combined chemotherapy regimens every three weeks.
The majority of agents administered included cisplatin
(80 mg/m2), or carboplatin (area under curve [AUC] 5)
plus vinorelbine (30 mg/m2), carboplatin (300 mg/m2) plus
gemcitabine (1200 mg/m2) or paclitaxel (175 mg/m2) and
cisplatin (70 mg/m2) plus gemcitabine (1250 mg/m2). Dose
reduction, treatment delay or completion were decided by
the treating physician using objective criteria (white blood
cell count, anemia, serum creatinine, gastrointestinal or
neurological symptoms) and performance status as subjec-
tive criteria. Sequential radiotherapy was administered in
selected patients. Laboratory testing was implemented
before each cycle to detect hematological, renal or hepatic
failure. At least 1.5 g/L absolute neutrophil count was
required to continue the therapy, and in the case of
patients with grade 3 or 4 neutropenia, granulocyte colony
stimulating factor (G-CSF) was used according to the
American Society of Clinical Oncology (ASCO) guidelines.
Follow-up visits were performed in the outpatient ward at
the Department of Pulmonology, University of Szeged,
Hospital of Chest Diseases every three, six, and 12 months
after the last dose of chemotherapy was administered.
Statistical analysis
Patient characteristics and chemotherapy protocol compli-
ance, toxicity, postoperative complications, and survival
data were compared between the intubated and non-
intubated groups. As data were not normally distributed,
we used Student’s t-test and Wilcoxon Mann-Whitney
two-sample test. All statistical analyses were performed
using SigmaPlot for Windows Version 12.0 software. A
value of P < 0.05 indicated a statistically significant
difference.
Results
Patient characteristics
There was no significant differences in age, gender, BMI,
ECOG status and smoking habits in all patients who
underwent either intubated or nonintubated VATS lobec-
tomies. There were also no significant differences in hema-
tological and pulmonary diseases, arrhythmia, former
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malignancies, or chronic kidney failure which have a nega-
tive impact on further oncological outcomes. We used the
modified, age-adjusted Charlson Comorbidity Index
(ACCI) to evaluate differences between the two groups
with regard to comorbidities and weighted based on
patients’ age, as it has previously been described that ACCI
is a better predictor factor of survival in lung cancer
patients who have undergone surgery. Using ACCI, we did
not detect any significant differences.26 Baseline pulmonary
function testing showed no significant differences in FEV1
and DLCO between intubated and nonintubated individ-
uals, in accordance with the lack of differences in the inci-
dence of COPD or asthma. Further baseline clinical
characteristics are provided in Table 1.
The incidence of adenocarcinoma and squamous cell
carcinoma cases were similar in both groups; however, the
pathological staging showed significant differences, as 18%
of nonintubated patients had IB lung cancer, compared to
the intubated group (P = 0.01) (Table 1). We observed no
differences in the type of anatomic pulmonary resections
(Table 2).
Adjuvant chemotherapy protocol
compliance and toxicity
All patients who were considered for the four-cycle
adjuvant chemotherapy regimen underwent lobectomy;
however, treatment refusal occurred in two cases among
Table 1 Main clinical characteristics and demographic data of patients who underwent intubated and nonintubated VATS lobectomies
Intubated (n = 38) Nonintubated (n = 28) P-value
Mean age (median) 64 (63) 63.03 (63) 0.075
Gender (n, %) Male:17 (45), Male: 7 (25) —
Female: 21 (55) Female: 21 (75)
BMI (kg/m2) 24.83  3.07 24.31  4.17 0.28
ECOG (n, %) 0.40
0 28 (74) 1 (68)
1 10 (26) 9 (32)
Smoking status (No.%) Never: 12 (32) Never: 10 (36) 0.46
Previously: 14(36) Previously: 5 (18) 0.07
Mean py = 33 Mean py = 30.6
Habitual: 12(32) Habitual: 13 (46) 0.16
Mean py = 30 Mean py = 35
Preoperative complications No. (%)
CHD 10 (26) 4 (14) 0.04
Hypertension 23 (60) 9 (32) 0.02
COPD or asthma 9 (24) 10 (36) 0.21
Former malignancy 3 (8) 4 (14) 0.33
Hematological diseases 3 (8) 2 (7) 0.64
Chronic kidney failure 3 (8) 1 (3.5) 0.43
Arrhythmia 6 (16) 4 (14) 0.57
Diabetes mellitus 4 (10) 2 (7) 0.49
ACCI (mean  SD) 5.56  1.4 5.18  1.62 0.20
FEV1 (L, mean  SD) 2.26  0.83 2.16  0.69 0.33
FEV1 (%, mean  SD) 87.45  20.24 87.54  19.24 0.49
DLCO (%, mean  SD) 64.15  18.45 68.92  16.43 0.20
Pathological types No. (%)
Adenocarcinoma 31 (82) 21 (75) 0.36
Squamous cell carcinoma 5 (13) 5 (18) 0.42
Other 2 (5) 2 (7) 0.56
Pathological staging No. (%)
IB 0 (0) 5 (18) 0.01
IIA 10 (26) 5 (18) 0.30
IIB 13 (34) 7 (25) 0.29
IIIA 15 (40) 10 (36) 0.47
IIIB 0 (0) 1 (3) 0.42
IIIC 0 (0) 0 (0) —
IVA 0 (0) 0 (0) —
IVB 0 (0) 0 (0) —
ACCI, age-adjusted Charlson Comorbidity Index; BMI, body mass index; CHD, chronic heart disease; COPD, chronic obstructive pulmonary disease;
py, pack-year; SD, standard deviation.
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the nonintubated patients. A total of 38 patients in the
intubated group and 26 patients in the nonintubated group
received platinum-based chemotherapy combined with
mostly vinca-alkaloid, taxane or gemcitabine. Significantly,
more carboplatin and taxane combinations was adminis-
tered in the nonintubated group (P = 0.03), than other che-
motherapy regimens. Among the nonintubated and
intubated patients, 85% and 92%, respectively, received full
dose schedule, meaning that patients were treated with a
full dose of chemotherapy regimens based on their body
surface or AUC 5 value in each cycle. The full dose sched-
ule is the received dose in mg in each cycle, calculated
based on patients’ demographic and laboratory data
(weight, height and renal function parameters). Dosage in
mg of adjuvant chemotherapy was initially determined and
not altered significantly by the multidisciplinary team and
oncologists, unlike the number of cycles. Dose reductions
occurred in patients with grade 3 or 4 toxicities and were
performed in each group without significant differences.
Radiotherapy was implemented sequentially in 5% of the
intubated and 15% of the nonintubated group without sig-
nificant differences (Table 3).
Nevertheless, significantly more grade 1 or 2 toxic symp-
toms including nausea, vomiting, anemia, thrombocytope-
nia, and neutropenia were reported in the intubated group
(P = 0.03). Additionally, grade 4 neutropenia requiring G-
CSF treatment was more likely to occur in the participants
in the intubated group, compared to those in nonintubated
group, showing no incidence (P = 0.03). Grade 3 or 4 ane-
mia and thrombocytopenia were not experienced in a sta-
tistically significant proportion between the groups
(Table 4).
A total of 51 (80%) patients completed the planned
four-cycle platinum-based chemotherapy according to pro-
tocols. Only 71% of patients in the intubated group
reached complete cycles, compared to 92% of the non-
intubated group, showing statistically significant differences
(P = 0.035). Therapy was discontinued in case of severe
adverse effects or patients refused further treatment
(Table 5).
Surgical and survival data analysis
Significantly less operation time was required for per-
forming the nonintubated surgical technique than the
intubated technique (91.04  23.88 vs. 125.77  38.07
minutes, P < 0.01). Chest tube duration analysis showed
that patients without intubation required the tube for
Table 2 Anatomic pulmonary resections
Number (%)
Intubated
(n = 38)
Nonintubated
(n = 28)
P-
value
Right upper lobectomy (RUL) 12 (32) 13 (46) 0.30
Right middle
lobectomy (RML)
4 (10.5) 2 (7) 0.47
Right lower lobectomy (RLL) 4 (10.5) 3 (11) 0.65
Left upper lobectomy (LUL) 10 (26) 6 (22) 0.40
Left lower lobectomy (LLL) 8 (21) 4 (14) 0.33
LLL, left lower lobectomy; LUL, left upper lobectomy; RLL, right lower
lobectomy; RML, right middle lobectomy; RUL, right upper lobectomy.
Table 3 Main general states of patients who received adjuvant
chemotherapy
Number (%)
Intubated
(n = 38)
Nonintubated
(n = 28)
P-
value
Cycles planned
4 38 (100) 28 (100) —
Treatment refusal 0 (0) 2 (7)
Treatment acceptance 38 (100) 26 (93)
Planned regimens received 27 (71) 24 (92) 0.035
Planned regimens
uncompleted
11 (29) 2 (7) 0.035
Chemotherapy regimens
Carboplatin + vinorelbine 23 (61) 14 (54) 0.39
Cisplatin + vinorelbine 14 (37) 5 (20) 0.16
Carboplatin + paclitaxel 1 (2) 5 (20) 0.03
Carboplatin + gemcitabine 0 (0) 1 (3) 0.40
Cisplatin + pemetrexed 0 (0) 1 (3) 0.40
Received full dose of
schedule
35 (92) 22 (85) 0.29
Received >75%
planned dose
3 (8) 3 (11) 0.46
Received <75%
planned dose
0 (0) 1 (4) 0.40
Toxicity grade 1/2 6 (16) 0 (0) 0.03
Toxicity grade 3/4 14 (37) 6 (23) 0.18
Radiotherapy 2 (5) 4 (15) 0.17
Table 4 Grade 3/4 hematological toxicity in patients who received
adjuvant chemotherapy
Number (%) Intubated Nonintubated P-value
Grade 3 neutropenia 6 (16) 5 (19) 0.48
Grade 4 neutropenia 6 (16) 0 (0) 0.03
Grade 3 anemia 1 (3) 1 (4) 0.65
Grade 4 anemia 0 (0) 0 (0) —
Grade 3 thrombocytopenia 1 (3) 0 (0) 0.59
Grade 4 thrombocytopenia 0 (0) 0 (0) —
Table 5 Protocol compliance in case of treatment acceptance
Number (%) Intubated Nonintubated P-value
Cycle I 38 (100) 26 (100) —
Cycle II 35 (92) 26 (100) 0.2
Cycle III 34 (89) 24 (92) 0.53
Cycle IV 27 (71) 24 (92) 0.035
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significantly fewer days, compared to those in the
intubated group (2.12  1.16 vs. 4.33  3.58, P < 0.01).
Moreover, postoperative complications, mainly subcutane-
ous emphysema, were encountered with higher incidence
in patients in the intubated group (P = 0.027) (Table 6).
We detected no postoperative mortality in either group.
Patients who received 1–4 cycles of chemotherapy showed
no significant differences in actual survival during follow-
up (Table 7).
Discussion
In this retrospective study, we compared oncological and
surgical features of 66 patients who had undergone either
intubated or nonintubated VATS lobectomies. There is
increasing evidence that minimally invasive techniques
result in better outcomes with regard to hospital stay,
blood loss, preserved pulmonary functions, immune
responses and there may even be oncological
advantages.27–29 VATS surgery contributes to the delivery
of adjuvant chemotherapy and a better compliance with
therapy protocols. Teh et al. found an improved compli-
ance, with earlier initiation of adjuvant platinum plus vin-
orelbine chemotherapy and a reduction in hematological
impact in NSCLC patients after VATS resections compared
to thoracotomy.9 Similarly, patients receiving docetaxel-
carboplatin adjuvant chemotherapy after VATS surgery
gained a well-tolerated protocol compliance with more
completion of the planned cycles.30 Moreover,
thoracoscopic pulmonary resections and lobectomies have
been reported to be associated with significantly fewer dose
reductions in patients and delays in therapy schedules.10, 31
Cisplatin plus gemcitabine, cisplatin plus vinorelbine and
carboplatin plus paclitaxel combined chemotherapy regi-
mens also showed better influence on therapy dosage, com-
pleted cycles and toxicity in case of NSCLC patients who
underwent VATS.32 In accordance with previous studies,
we found that patients who were treated with nonintubated
approach had further remarkable benefits when adminis-
tered adjuvant chemotherapy. Compared to the conven-
tional VATS technique, after uniportal nonintubated
lobectomies we detected a higher proportion of patients
who received full four-cycle regimens, resulting in better
protocol compliance.
The avoidance of general anesthesia and one-lung
mechanical ventilation could result in a better physiological
inflammatory response, a better conserved lymphocyte and
NK cell population; furthermore, the extent of surgical
invasiveness has been shown to play a key role in immune
response to surgery.4, 33–35 It is well established that a
thoracoscopic approach has immunological and clinical
advantages over thoracotomy; however, few data exist on
the long-term oncological effects in patients in which a
nonintubated VATS procedure has been performed. As the
secretion of interleukins, especially IL-10, are able to medi-
ate an escape of tumor cells from the host immune system
and inhibit NK-cell mediated cytotoxicity, it could partly
explain tumor recurrence and the poor prognosis associ-
ated with thoracotomy.36, 37 Therefore, a nonintubated
procedure should bring about cellular immune response
benefits, a reduction in morbidity, shorter hospital stay and
reduced postoperative thorax drainage compared to the
conventional VATS technique.12, 38 A recent study proved
that nonintubated lung metastasectomy resulted in fewer
immune-depressive effects, with a lower morbidity rate,
and better survival after NITS in malignant pleural effusion
cases.39
Consequently, we hypothesized that as NITS may have
less impact on cellular responses in patients that it might
provide further oncological and clinical advantages. We
evaluated the dosage on schedule, compilation of planned
chemotherapy cycles and toxicity to reach conclusions in
terms of protocol compliance. We detected significant tox-
icity differences between the patients in the intubated and
nonintubated groups, since a greater percentage of patients
who underwent conventional VATS showed grade 1/2 tox-
icity and grade 4 neutropenia compared with those who
underwent NITS. Chest tube duration and operation time
were also significantly reduced in patients who underwent
NITS, and that could have an enormous impact on hospi-
talization and postoperative complications. Theoretically,
these differences could be attributable to immune factors
influenced by minimally invasive techniques. If so, further
randomized studies are needed to reach a conclusion
regarding the association between the lack of intubation
procedure and long-term oncological outcomes.
Table 7 Survival data (n = 66)
Number (%) Intubated Nonintubated P-value
Postoperative mortality 0 (0) 0 (0) —
Actual survival
Alive 30 (79) 26 (93) 0.11
Deceased during follow-up 8 (21) 2 (7)
Table 6 Postoperative results
Intubated Nonintubated P-value
Operation time
(minutes)
125.77  38.07 91.04  23.88 <0.01
Days of chest tube 4.33  3.58 2.12  1.16 <0.01
Postoperative complications
Subcutaneous
emphysema
4 (10.5) 0 (0) 0.027
Fever 0 (0) 0 (0)
Reoperation 2 (5.2) 0 (0)
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To our knowledge, this is the first study that has rev-
ealed a better response to chemotherapy after nonintubated
video-assisted lobectomies over traditional intubated VATS
lobectomies. However, there are some limitations in our
study because of the limited number of patients included
and its retrospective nature. Our results are consistent with
former findings and support the efficacy of minimal inva-
siveness on adjuvant chemotherapy; nevertheless, this is
still a controversial field due to the limited clinical data
available. Based on our observations, we highlight the
necessity of further clinical and basic studies to reach
proper conclusions regarding associations between inflam-
matory, cellular responses and clinical benefits of adjuvant
chemotherapy following nonintubated video-assisted
lobectomy.
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